HPV Vaccine Works to Prevent HPV and Cervical Cancers


Arbyn, M., Xu, L., Simoens, C., & Martin‐Hirsch, P. P. (2018). Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews, (5).

Arrossi, S., Paolino, M., Laudi, R., Gago, J., Campanera, A., Marín, O., … & Thouyaret, L. (2019). Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in Argentina: a population-based, before-and-after retrospective cohort study. The Lancet Global Health, 7(6), e772-e783.

Castellsague, X., Munoz, N., Pitisuttithum, P., Ferris, D., Monsonego, J., Ault, K., … & Bryan, J. (2011). End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. British journal of cancer, 105(1), 28.

Schwarz, T. F., Huang, L. M., Lin, T. Y., Wittermann, C., Panzer, F., Valencia, A., … & Descamps, D. (2014). Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10-to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial. The Pediatric infectious disease journal, 33(12), 1255-1261

Schwarz, T. F., Galaj, A., Spaczynski, M., Wysocki, J., Kaufmann, A. M., Poncelet, S., … & Struyf, F. (2017). Ten‐year immune persistence and safety of the HPV‐16/18 AS 04‐adjuvanted vaccine in females vaccinated at 15–55 years of age. Cancer medicine, 6(11), 2723-2731.

Simms, K. T., Steinberg, J., Caruana, M., Smith, M. A., Lew, J. B., Soerjomataram, I., … & Canfell, K. (2019). Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study. The Lancet Oncology, 20(3), 394-407.